PT3394083T - Derivados de n-[5-[(3,4-dimetoxifenil)metil]-1,3,4-tiadiazol-2-il]-2-metoxi-benzenoacetamida e compostos relacionados como ativadores de cftr para tratar a obstipação ou colestase - Google Patents
Derivados de n-[5-[(3,4-dimetoxifenil)metil]-1,3,4-tiadiazol-2-il]-2-metoxi-benzenoacetamida e compostos relacionados como ativadores de cftr para tratar a obstipação ou colestaseInfo
- Publication number
- PT3394083T PT3394083T PT168801561T PT16880156T PT3394083T PT 3394083 T PT3394083 T PT 3394083T PT 168801561 T PT168801561 T PT 168801561T PT 16880156 T PT16880156 T PT 16880156T PT 3394083 T PT3394083 T PT 3394083T
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- cftr
- regulators
- cftr regulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Prostheses (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387591P | 2015-12-24 | 2015-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3394083T true PT3394083T (pt) | 2021-12-07 |
Family
ID=59091233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT168801561T PT3394083T (pt) | 2015-12-24 | 2016-12-23 | Derivados de n-[5-[(3,4-dimetoxifenil)metil]-1,3,4-tiadiazol-2-il]-2-metoxi-benzenoacetamida e compostos relacionados como ativadores de cftr para tratar a obstipação ou colestase |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190031630A1 (OSRAM) |
| EP (1) | EP3394083B9 (OSRAM) |
| JP (1) | JP6894902B2 (OSRAM) |
| KR (1) | KR102723194B1 (OSRAM) |
| CN (1) | CN108699107B (OSRAM) |
| AU (2) | AU2016377782B2 (OSRAM) |
| CL (1) | CL2018001714A1 (OSRAM) |
| CO (1) | CO2018007239A2 (OSRAM) |
| ES (1) | ES2901002T3 (OSRAM) |
| IL (2) | IL299924B2 (OSRAM) |
| PL (1) | PL3394083T3 (OSRAM) |
| PT (1) | PT3394083T (OSRAM) |
| RU (1) | RU2742934C2 (OSRAM) |
| WO (1) | WO2017112947A1 (OSRAM) |
| ZA (1) | ZA201804228B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3066112T3 (en) | 2015-12-24 | 2026-05-11 | The Regents Of The Univ Of California | Cftr regulators and methods of use thereof |
| IT201700085714A1 (it) * | 2017-07-26 | 2019-01-26 | Luigi Maiuri | Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine. |
| EP3672598A4 (en) * | 2017-08-24 | 2021-04-28 | The Regents of The University of California | OCULAR PHARMACEUTICAL COMPOSITIONS |
| FR3096890B1 (fr) * | 2019-06-07 | 2021-05-14 | H4 Orphan Pharma | Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique. |
| US20220071549A1 (en) * | 2020-09-08 | 2022-03-10 | The Regents Of The University Of California | Apparatus, systems and methods of use for ocular surface potential difference measurement |
| PY2193067A (es) | 2020-10-23 | 2022-06-20 | Ildong Pharmaceutical Co Ltd | Compuestos moduladores del cftr, composiciones y usos de estos |
| CN113527225B (zh) * | 2021-07-15 | 2022-11-18 | 南昌大学 | 一种丙烯酰噻二唑衍生物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1917999A (en) | 1998-03-31 | 1999-10-18 | Warner-Lambert Company | Quinoxalinones as serine protease inhibitors such as factor xa and thrombin |
| AP2005003292A0 (en) * | 2002-09-30 | 2005-06-30 | Univ California | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| WO2005075435A1 (en) * | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US20090105240A1 (en) * | 2007-10-17 | 2009-04-23 | Tomas Mustelin | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same |
| AU2009221327B2 (en) | 2008-03-05 | 2014-03-27 | Merck Patent Gmbh | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| US8314239B2 (en) | 2008-10-23 | 2012-11-20 | Vertex Pharmaceutical Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2010073011A2 (en) * | 2008-12-23 | 2010-07-01 | Betagenon Ab | Compounds useful as medicaments |
| TWI450891B (zh) * | 2010-12-29 | 2014-09-01 | Dev Center Biotechnology | 新穎微管蛋白抑制劑 |
| AU2015229188A1 (en) * | 2014-03-13 | 2016-09-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
| EP3157917B1 (en) | 2014-06-19 | 2020-03-18 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
-
2016
- 2016-12-23 ES ES16880156T patent/ES2901002T3/es active Active
- 2016-12-23 US US16/016,300 patent/US20190031630A1/en not_active Abandoned
- 2016-12-23 CN CN201680082474.2A patent/CN108699107B/zh active Active
- 2016-12-23 AU AU2016377782A patent/AU2016377782B2/en active Active
- 2016-12-23 RU RU2018126959A patent/RU2742934C2/ru active
- 2016-12-23 KR KR1020187021185A patent/KR102723194B1/ko active Active
- 2016-12-23 IL IL299924A patent/IL299924B2/en unknown
- 2016-12-23 EP EP16880156.1A patent/EP3394083B9/en active Active
- 2016-12-23 WO PCT/US2016/068561 patent/WO2017112947A1/en not_active Ceased
- 2016-12-23 PL PL16880156T patent/PL3394083T3/pl unknown
- 2016-12-23 PT PT168801561T patent/PT3394083T/pt unknown
- 2016-12-23 JP JP2018533127A patent/JP6894902B2/ja active Active
-
2018
- 2018-06-21 CL CL2018001714A patent/CL2018001714A1/es unknown
- 2018-06-21 IL IL260210A patent/IL260210B2/en unknown
- 2018-06-22 ZA ZA2018/04228A patent/ZA201804228B/en unknown
- 2018-07-11 CO CONC2018/0007239A patent/CO2018007239A2/es unknown
-
2019
- 2019-10-28 US US16/666,278 patent/US11192869B2/en active Active
-
2021
- 2021-10-26 AU AU2021257948A patent/AU2021257948B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2400028I1 (hu) | PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások | |
| IL286316A (en) | New micro-dystrophins and related method of use | |
| IL282572B (en) | Tetrahydropyranylamino-pyrrolopyrimidinone and methods of using it | |
| IL289976A (en) | Oxysterols and methods of using them | |
| IL256179A (en) | lag-3 binding molecules and methods of using them | |
| IL250415B (en) | Antibodies against pd-l and methods of using them | |
| IL256710B1 (en) | Oxysterols and methods of using them | |
| PL3548033T3 (pl) | Związki i sposoby ich stosowania | |
| SG11201803213XA (en) | Glycan-interacting compounds and methods of use | |
| SG10201912087SA (en) | Anti-sortilin antibodies and methods of use thereof | |
| IL282482A (en) | Variants of protoxin-II and methods of use | |
| ZA201804228B (en) | Cftr regulators and methods of use thereof | |
| IL282508A (en) | Variants of protoxin-II and methods of use | |
| ZA201804230B (en) | Cftr regulators and methods of use thereof | |
| ZA201804229B (en) | Cftr regulators and methods of use thereof | |
| SG10201912615PA (en) | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |